Ascending single dose study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAM-531 administered orally to healthy subjects
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Wyeth
- 27 Jul 2007 New trial record.